TP53 and cancer: Since p53 has been found to be mutated or functionally deactivated in most of the cancers, targeting E2F1-mediated apoptosis in response to DNA damage signals can provide as an additional therapeutic means (Polager and Ginsberg, 2009; Wu and Yu, 2009).